- Investing Ideas
- /
- U.S. Pharmaceuticals & Biotech Undervalued Stocks Based On Cash Flows
U.S. Pharmaceuticals & Biotech Undervalued Stocks Based On Cash Flows
Results
12
0 new
Companies with promising cash flow potential yet trading below their fair value, as determined by SWS DCF valuation, signaling opportunity for value-oriented investors.
12 companies
| Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | ||
|---|---|---|---|---|---|---|---|---|---|---|
INCY | US$72.11 | 2.4% | 19.0% | US$14.0b | US$78.26 | PE427.9x | E22.3% | n/a | ||
ABBV | US$202.08 | 4.8% | 13.5% | US$356.7b | US$204.90 | PE84.2x | E25.3% | 3.2% | ||
GILD | US$109.95 | 5.6% | 49.5% | US$137.0b | US$107.59 | PE285.5x | E23.6% | 2.9% | ||
SHC | US$13.52 | 0.3% | -19.6% | US$3.8b | US$16.06 | PE54.3x | E28.4% | n/a | ||
ONC | US$255.37 | 10.6% | 64.6% | US$27.3b | US$285.04 | PS8.4x | E67.0% | n/a | ||
BLFS | US$26.67 | -4.0% | 52.4% | US$1.2b | US$31.00 | PS8.4x | E63.3% | n/a | ||
VCYT | US$39.18 | -4.7% | 76.6% | US$3.0b | US$45.11 | PS7.1x | E46.2% | n/a | ||
CDXC | US$5.42 | -7.7% | 256.6% | US$414.9m | US$7.96 | PE279.4x | E81.8% | n/a | ||
VRTX | US$484.24 | 5.5% | 12.6% | US$124.3b | US$497.91 | PS11.3x | E29.4% | n/a | ||
LLY | US$873.68 | 3.5% | 13.5% | US$784.7b | US$981.47 | PE74.1x | E21.7% | 0.7% | ||
RGEN | US$158.99 | 8.2% | -19.1% | US$8.9b | US$193.80 | PS14x | E43.4% | n/a | ||
BRKR | US$50.82 | 1.6% | -40.0% | US$7.7b | US$68.42 | PE68.1x | E61.3% | 0.4% |
Page 1 of 1